Celltrion Wins Brazilian Trastuzumab and Rituximab Tender
As Company Aims to Lead Latin American Biosimilar Market
Celltrion has won a Brazilian tender to supply two oncology biosimilars – Herzuma (trastuzumab) and Truxima (rituximab) – to the Brazilian market. Based on its successful bid in Brazil, the company plans on expanding its direct sales business model to Peru and Chile in the third quarter of this year.
